The aim of the study was to perform a comprehensive analysis of patients with a benign final histology after pancreaticoduodenectomies (PD) for suspected pancreatic and periampullary cancer. material and methods. We searched the pathology database at the King's College Hospital for negative PD specimens submitted between January 2004-December 2010. Clinical, diagnostic, surgical, histopathological and outcome data were collected retrospectively. Pathology specimens and imaging results have been re-evaluated. A literature review was performed to identify factors affecting the incidence across centres. Results. 469 PD were performed for presumed cancer. The incidence of benign disease encountered in this group was 7.25% (34/469). Autoimmune pancreatitis (AIP) was a finding in 26.47% (9/34) of cases. 17.65% of PD were complicated by a pancreatic leak and the overall mortality rate was 8.82% (3/34). Radiologists revised over 75% of pre-operative diagnoses. The incidence of benign disease was correlated with the overall centre experience and utilisation of CT imaging, but not ERCP or EUS. conclusions. It is impossible with current diagnostics to entirely avoid cases of benign disease in patients undergoing PD for suspected cancer. The mortality rate is higher in this group, but it is possible to avoid unnecessary procedures in experienced centres. AIP represents an important diagnostic entity, which should be actively pursued pre-operatively.
Pancreaticoduodenectomy (PD) (Whipple's procedure) is considered a well-established and potentially curative treatment for head of pancreas (HOP) and periampullary malignancies (1) . Advances in surgical technique, perioperative care and concentration of surgery in large volume centres have significantly improved mortality and morbidity associated with the procedure (2, 3) . However, published data still quote mortality rates varying between 0% and 9.3%, with higher figures in clinical practice (4) . Morbidity remains high at 25% even in centres reporting no mortality (5) . Thus, PD may better be avoided in patients with benign disease, when less invasive treatment options are available. In patients where the diagnosis of cancer is uncertain resection is still recommended (6) .
The diagnostic work-up for patients with presumed cancer is complex, costly and not always accurate as shown by Barone (7) . A recent literature review of PD for presumed cancer showed the collected incidence of cases with a final benign histopathology to be as high as 13 .1% (7) . Previous studies have showed a wide range of benign disease mimicking cancer, including chronic pancreatitis, the newly recognized steroid responsive autoimmune pancreatitis (AIP) (8) , groove pancreatitis, benign biliary tract and duodenal disease (9) and more rarely tuberculosis (10) and Crohn's disease (11) . This paper presents our recent experience of PD performed for suspected cancer, where the final histology was negative for malignancy. This study reports the operative outcome, incidence and spectrum of benign disease encountered in these patients.
The aim was to evaluate the presenting characteristics, clinical and radiological findings in the light of the final histopathological diagnosis together with a review of the literature trying to improve the diagnosis further.
MATERIAL AND METHODS

Study group
The pathology database at the Institute of Liver Studies, King's College Hospital has been searched for PD specimens submitted between January 2004 and December 2010. All patients with presumed pancreatic cancer referred to the department are discussed in a dedicated Multidisciplinary Meeting (MDM) which involves surgeons, radiologists, oncologists, gastroenterologists, pathologists, clinical nurse specialist and palliative care clinicians. The indication for surgery was obtained by reviewing the MDM outcomes/decisions recorded in our database. Cases with a presumed malignant pre-operative diagnosis and a benign final histopathology result have been selected for this analysis. Patients who underwent PD for benign disease have been excluded. The histopathology reports, complete medical records and radiological investigations were reviewed. Recorded characteristics included: age, gender, history of pancreatitis, presenting symptoms (pain, jaundice, weight loss), imaging modality, tumour marker levels, IgG serology (where available), MDM outcome, 90 day mortality, hospital stay, pancreatic leak rate, reoperation, ITU admission and final histopathology result.
Histopathological review
Histological and where appropriate immunohistochemical review was performed by an experienced histopathologist. The slides were re-examined by a single histopathologist (YZ) to review the final diagnosis.
Radiological review
A retrospective analysis based on the available imaging data of patients with a presumed diagnosis of cancer and a final benign histology was performed independently by 2 radiologists (PP and RJ) experienced in HPB imaging, who were blinded to the previous reports and final histopathological diagnosis, but were aware of the negative pathology results. The final radiological diagnosis was reached by consensus between the 2 reviewers and compared with the initial pre-operative diagnosis and final histopathology result.
Literature review
Publications from 2000 onwards, which reported the incidence of benign disease in patients undergoing PD for a presumed diagnosis of cancer were selected for review. Studies reporting the overall incidence of benign disease were not considered for analysis. The recorded values included reported incidence, number of studied patients, cases performed per year (cases/year) and percentage of patients having CT, ERCP and EUS. Using the Pearson correlation coefficient we compared the incidence against the other values to identify any dependent relationships. For the statistical analysis SPSS version 17.0, IBM, Chicago, USA has been used.
RESULTS
Clinical data
From January 2004 to December 2010 a total of 482 PD were performed in our department, of these 469 for presumed pancreatic of periampullary malignancy. 13 patients underwent surgery for benign diseases (tab. 1), confirmed by the subsequent histology. None of these patients were found to have malignant disease on final histology. Of the 469 cases performed for presumed cancer 34 (7.25%) were found to be benign after histopathological examination. 19 where male, 15 female with a mean age of 60.5 years (range: 34-77 years). Two of these patients had a previous history of pancreatitis and one patient had a history of Sjögren's syndrome. The presenting symptoms were variable with jaundice, pain or weight loss each being present in approximately half of the patients (tab. 2). CA19-9 levels were available in 28 out of the 34 patients with levels >37 U/ml present only in 8. In over 20% of cases the abnormality, which lead to the suspicion of malignancy was discovered incidentally on imaging.
Radiological results
The pre-operative imaging has been summarised in tab. 3. Of 34 cases, the imaging of 21 (21 CT, 6 MRI) was available for retrospective analysis. The radiologists revised the pre-operative diagnosis in 17 patients (81%). On CT imaging a mass could be identified in Pre-operative working diagnosis
The indication for surgery was ampullary malignancy in 7 cases (20.59%), distal bile duct carcinoma in 7 cases (20.59%), duodenal malignancy in 2 patients (5.88%), HOP malignancy in 17 patients (50%) and IPMN (Intraductal Papillary Mucinous Neoplasm) in one case (2.94%).
Histopathology results
The final histopathology revealed a wide spectrum of diseases. In tab. 4 all the histopahological results have been presented according to the presumed pre-operative diagnosis. Features of chronic pancreatitis were present in 16 cases (47.05%) with 9 (26.47%) confirmed as AIP (8-IgG4-related/ type 1, 1-non-IgG4 related/ type 2) (12). Out of these only one patient had serological IgG4 studies performed Benign histology after pancreaticoduodenectomy for suspected malignancy. Lessons to be learned before the procedure, while in one IgG4 studies were performed postoperatively. These showed a raised IgG4 level and both patients had AIP type 1 on final histology. In two specimens pre-malignant disease consistent with PanIN (Pancreatic Intraepithelial Neoplasia) and a 4 mm atypical stromal tumour were discovered incidentally. In 2 patients no abnormal findings could be identified.
Operative outcome
The recorded perioperative mortality rate was 8.82% with 3 patients dying within 90 days of surgery. The first patient developed mesenteric ischaemia post-operatively and died 6 days after the resection. In the second case the patient died on the 20 th post-operative day of sepsis that developed on the back-  Non-specific (1)  AIP (7) o Type 1, IgG4 related (6) o Type 2, non-IgG4 related (1) Focal biliary epithelial dysplasia (1) Biliary and ampullary reactive changes (1) Cholangitis (2) Distal bile duct carcinoma* (7) Chronic pancreatitis (AIP type 1) (2) Non-specific cholangitis (2) Choledocholithiasis (2) Chronic sclerosing cholangitis (1) Duodenal malignancy* (2) Duodenal ulcer (1) Duodenal cystic dystrophy (1) ground of a pancreatic leak and pneumonia. The third patient died on day 26 after the operation due to major gastrointestinal bleeding from a ruptured pseudoaneurysm. 44% of patients were admitted to an intensive care unit post-operatively while the rest were treated in a high dependency area before transfer to a ward environment. A total of 3 patients required further surgical intervention. The first patient was re-operated for an evacuation of a subphrenic haematoma and a colonic fistula repair. The second underwent a right hemicolectomy for large bowel necrosis following artery embolization due to bleeding. The third case was an attempt at debridement and a peritoneal wash in a septic patient, who subsequently died. In this cohort of patients the pancreatic leak rate was 17.65% (pancreatic leak defined as: output of amylaserich fluid (>300 U/l) on or after the fifth post-operative day) (13) . A third (33%) of patients, who developed a pancreatic leak died compared with 3.57% of patients without the complication (OR 13.50; Fisher exact test: p-value: 0.07). The median hospital stay was 12 days (range: 7-43).
Statistical comparison with other studies Table 5 summarises the results of the analysis. The Pearson correlation test did not show any significant relationship between the incidence of benign disease reported and the average number of cases operated per year or percentage of patients having ERCP or EUS as pre-operative imaging. However, there was a statistically significant correlation for the size of the patient cohort studied (Pearson correlation coefficient: -0.787; p-value: 0.02) and percentage of patients having a CT scan preoperatively (Pearson correlation coefficient: -0.937; p-value: 0.019).
DISCUSSION
The incidence of benign disease in patients undergoing a PD for presumed cancer varies between different units. In this study it was 7.25%, which is similar to the results reported by Hurtuk et al. (7.8%) (14) and de la Fuente et al. (7.4%) (15) and is lower than the quoted average (7). The spectrum of benign disease encountered is broad and includes conditions affecting the pancreatic tissue, biliary system, ampullary region and duodenum. We found a higher incidence of inflammatory conditions affecting the biliary system in this patient group, which has not been reported previously (9, 16, 17) and half of the patients having of some form of chronic pancreatitis. AIP is a rare (2% of chronic pancreatitis cases) chronic inflammatory disease of the pancreatic gland (18). Our data supports previous reports showing that AIP represents a significant subgroup of benign disease encountered in patients operated for suspected pancreatic malignancy (9, 19 (9) . Currently 2 distinct histological subtypes have been recognized. Type 1, also often referred to as lymphoplasmacytic sclerosing pancreatitis, is thought to be the most common form of AIP and is characterised by a periductal lymphoplasmacytic infiltration of IgG4 positive plasma cells, storiform fibrosis and obliterative phlebitis (20) .
The histological appearance of AIP type 2 or idiopathic duct centric pancreatitis, shows neutrophil infiltrates around the pancreatic duct epithelium (granulocytic epithelial lesions) (21, 22). In 2001 Hamano et al. (23) showed that serum IgG4 levels are increased in patients with AIP type 1, but not in type 2 and these entities are recognized as IgG4-related and non-IgG4-related (8) . Therefore, AIP type 1 as opposed to type 2 is believed to be a manifestation of IgG4-related systemic disease (24). 30% of patients with AIP type 2 have associated inflammatory bowel disease (25) .
As AIP type 1 can be successfully treated with corticosteroids a pre-operative diagnosis could potentially reduce the number of cases mistaken for cancer and avoid the risks associated with surgery. Serum IgG4 levels are elevated in AIP type 1 and are therefore used as one of the diagnostic criteria to identify the condition in conjunction with clinical, radiological and histological findings (26, 27). Serum IgG4 titres have been found to differ significantly between AIP, healthy controls and pancreatic cancer (28, 29) . Learn et al. suggests that for this reason IgG4 serology should be widely used to identify AIP in patients with presumed cancer to prevent unnecessary surgery (30) .
Other studies however, have raised alertness by reporting high IgG4 levels in malignant cases (31, 32) . AIP responds dramatically to corticosteroid treatment and some centres include steroid responsiveness as an extended diagnostic criterion for this condition (33) . However, subjecting patients with presumed cancer to immunosuppressive therapy and delaying surgical intervention remains controversial and needs to be justified (8) . On imaging AIP type 1 classically produces a characteristic peri-pancreatic capsule-like rim (34) and rarely leads to strictures with pancreatic duct dilatation (8) . AIP is a disease likely to relapse after cessation of steroid treatment, although based on 2 studies and for yet unknown reasons, the relapse free survival seems to be significantly higher and relapse rate lower in patients after PD (24, 35) .
In terms of presenting symptoms, Kennedy et al. reported similar figures except for a higher proportion of patients presenting with weight loss (80% compared with 47%) (16) . Most of these patients in our study were found to have some form of chronic pancreatitis while other benign conditions tended to present with either jaundice or pain only. It is important to note that pain was only present in approximately half of the patients. We did not observe a male predominance in our patient cohort, which has been a common finding in other reports (16, 19, 36) . Alcohol-induced pancreatitis was not a common diagnosis among specimens resected for presumed cancer, whereas the opposite is true for cases with known benign disease. This indicates that a history of heavy alcohol consumption and previous presentations with pancreatitis might be helpful in establishing the diagnosis. In our group only 2 patients had a confirmed history of pancreatitis. Though previous reports show a statistically significant difference in some presenting symptoms between benign and malignant cases in practice they tend to be unreliable.
Performing a PD when the diagnosis is uncertain is still considered acceptable, however it is clear that pancreatic centres are aware of the high mortality rate associated with PD and aim to keep the number of patients undergoing surgery with known benign disease low: Abraham (7 cases) (9), de Castro (8 cases) (36), our study (13 cases). The mortality rate reported in our study is higher than the 2% widely quoted in the literature (37) , but similar to the 5.1% reported by Manzia (17) . The higher mortality in this group is likely to be related to the higher pancreatic leak rate, which in turn is associated with the performance of a pancreaticojejunostomy in an often non-dilated pancreatic duct or a soft pancreas in cases, where there was no background pancreatitis or inflammation affecting the pancreas.
The statistical analysis performed on data reported in the literature revealed a significant correlation between the incidence of benign disease and the size of the patient group studied. These results imply that the overall experience might have a direct impact on the successful identification of non-neoplastic cases, which is reflected by the low incidence of benign disease among patients with suspected cancer in large volume centres. Another finding includes the inverse correlation between the incidence and the number of patients having a pre-operative CT scan. This confirms the importance of CT imaging in the diagnostic process and could perhaps explain the high incidence reported by Tessler (38) to be related to the fact that not all patients had CT imaging prior to surgery. No relationship could be identified for patients without ERCP or EUS suggesting that the intensity of utilizing these imaging modalities has little effect on the final diagnostic accuracy in identifying non-neoplastic disease. This is in keeping with Barone, who demonstrated that the incidence did not decrease over the last 20 years, despite the introduction of more sophisticated imaging techniques (7) .
In our study almost 75% of patients had EUS and none could be correctly diagnosed as benign pre-operatively. Hurtuk et al. reported a similar incidence of benign disease utilizing EUS in only 20% of their patients (14) . This can be explained by the suboptimal performance of EUS in distinguishing malignant from benign disease mimicking cancer. Based on 17 cases, were both EUS reports and reviewed CT data were available, we found that compared to CT, EUS was more likely to identify inflammatory changes as focal mass lesions (14/17-mass on EUS, 2/17-mass on CT), which is probably related to the appearance of parenchymal inflammation on ultrasound. A finding of a mass with additional features on EUS like duct strictures/ dilitaton, enlarged lymph nodes or duct thickening and a clinical picture suggestive of cancer is misleading in cases of non-malignant disease, as the results do not favour a benign diagnosis. Although EUS-FNA has a reported diagnostic specificity of 94% (39) and has lead to a significant improvement in the pre-operative diagnosis of pancreatic cancer and number of futile procedures (40) in practice it still fails to convince (41) . The comparison of the consensus diagnoses at the MDM pre-operatively, the revised radiological diagnoses and final histolopathological results are illustrated in Table 6 . The retrospective radiological review revealed that the most commonly missed diagnosis was benign disease affecting the distal common bile duct, the pancreaticoduodenal groove (paraduodenal pancreatitis, groove pancreatitis, duodenal cystic dystrophy) and AIP, of which the last two are nowadays routinely identified. The reviewers were able to retrospectively call the correct diagnosis in almost half of the cases (10 out of 21) based only on the radiological imaging. It is worth mentioning that initial radiol-ogy reports identified a mass in 20 out of 34 cases (59%), whereas after revising the imaging a mass could only be identified in 3 cases out of 21 (14%). The observed discrepancy between the initial pre-operative and reviewed diagnoses could be explained by the fact that both AIP and paraduodenal pancreatitis are relatively new recognised clinical entities. Interestingly, the radiologists reviewing the cases did not revise their call in 5 patients (4 ampullary tumours and 1 distal bile duct cholangiocarcinoma) with 4 demonstrating the 'double duct sign'. Double, pancreatic and biliary duct dilatation is associated with malignancy in 66% of cases representing pancreatic head cancer or distal cholangiocarcinoma (42) .
In our cohort 13 (38%) patients had a stent placed during ERCP in order to relieve the jaundice prior to staging CT. Stent placement during ERCP has been associated with reactive changes in the surrounding pancreatic parenchyma that affects the interpretation of CT or EUS (43, 44) . Fisher et al, however, have reported that the inflammatory reaction caused by the endoprosthesis insertion does not affect the diagnostic accuracy of EUS-FNA (45) .
When it comes to the assessment of patients with findings highly suspicious for cancer clinicians tend to adopt the attitude of Doubting Thomas by having a low threshold for surgery in order to provide direct evidence. A potential option in increasing pre-operative diagnosis is the use of EUS-trucut biopsy (EUS-TCB). The diagnostic accuracy of EUS-TCB in cases of AIP, which represents a significant subgroup of benign disease, has been shown to be superior to EUS-FNA in many studies (46 -49). Additionally, acquiring an ampullary biopsy for IgG4 staining has been shown to support the diagnosis of AIP (50) . However, considering that most patients with presumed cancer will have a malignant finding on final histopathological examination invasive pre-operative testing should not be considered in all patients. Less invasive methods like EUS elastography have been attempted to improve the differentiation of neoplastic and benign pancreatic mass lesions. Though, this technique is able to identify some conditions like autoimmune pancreatitis (51), it is not accurate enough to distinguish benign from malignant conditions (52, 53). The most recent data suggests that it is not going to replace EUS-FNA, but can provide additional information on tissue elasticity (tumours are usually harder than the surrounding parenchyma), therefore help to characterize lymph nodes and differentiate focal pancreatic lesions from normal tissue or benign inflammatory processes (54).
Our data suggests that CT imaging is imperative in the diagnosis of benign disease in patients with a suspected malignancy as the incidence of non-cancerous cases is directly correlated to the utilisation of this imaging modality. We have also found that CT is better at identifying benign disease compared to EUS and that the results of the latter modality can sometimes be misleading as the imaging features of benign disease are often misinterpreted as those of cancer. Lastly, our retrospective analysis of the imaging data, based mainly on CT, has led to the revision of the diagnosis in 81% of the studied cases, with a correct diagnosis identified in almost 50%. These arguments suggest that the correct diagnosis of benign disease among patients with suspected pancreatic and periampullary cancer is dependent on adequate CT imaging and that a careful interpretation of results by a radiologist experienced in HBP imaging could possibly improve diagnositic accuracy.
To conclude, this analysis reports our most recent experience of PD performed for cancer, but with benign disease on final histology. The spectrum of benign disease found in patients with presumed cancer is broad, but emerging diagnoses such as AIP and groove pancreatitis should be considered and their diagnosis actively pursued in circumstances where clinical or radiological findings raise the suspicion of a non-malignant process as non-operative management is preferred. Pre-operative CT imaging is critical for an accurate diagnosis and should be obtained prior to attempted biliary stenting. The incidence of benign disease is independent of the use of ERCP and EUS in the diagnostic process. We demonstrated that in cases with suspected cancer EUS is not accurate enough to differentiate between malignant and benign disease mimicking cancer. However, EUS-FNA still fails to convince clinicians of a benign diagnosis, despite a high specificity, because of the fear associated with the potential risk of missing cancers. As long as pre-operative diagnostics will not guarantee a correct diagnosis of benign and malignant disease in all patients, the finding of non-neoplastic disease among provided patients are managed by multidisciplinary teams in experienced, centralised, large volume centres.
patients operated for suspected cancer will remain a necessary sacrifice. Nevertheless, the incidence of benign findings can be minimised,
